Related Experiment Video
Updated: Dec 10, 2025
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Platelet inhibition by ticagrelor is protective against diabetic nephropathy in mice
Melissa Uil1, Loes M Butter1, Nike Claessen1
1Department of Pathology, Amsterdam UMC, location AMC, University of Amsterdam, Amsterdam, The Netherlands.
Insights
Ticagrelor, a platelet inhibitor, significantly protected against kidney damage in diabetic mice. It reduced inflammation, fibrosis, and preserved kidney function, highlighting its therapeutic potential for diabetic nephropathy.
Area of Science:
- Nephrology
- Cardiovascular Research
- Pharmacology
Background:
- Diabetic nephropathy (DN) is a severe diabetes complication linked to increased cardiovascular mortality.
- Elevated platelet activity contributes to DN pathogenesis, inflammation, and fibrosis.
- Platelets play a critical role in the progression of diabetic kidney disease.
Purpose of the Study:
- To investigate the protective effects of ticagrelor-induced platelet inhibition on the development of diabetic nephropathy.
- To evaluate ticagrelor's impact on renal injury markers and pathways in a mouse model of DN.
Main Methods:
- Diabetic nephropathy was induced in mice via unilateral nephrectomy and streptozotocin injections.
- Mice received ticagrelor (300 mg/kg) or vehicle every other day for 16 weeks.
- Evaluated urinary albumin excretion, glomerular and tubular histology, inflammatory markers, and cell apoptosis.
Main Results:
- Ticagrelor treatment significantly reduced urinary albumin excretion in diabetic mice.
- It prevented mesangial matrix expansion, podocyte effacement, and glomerular endothelial cell injury.
- Ticagrelor inhibited collagen IV deposition, macrophage infiltration, and reduced tubular inflammation and apoptosis.
Conclusions:
- Ticagrelor-induced platelet inhibition demonstrates significant renoprotective effects in a mouse model of diabetic nephropathy.
- The protective mechanism likely involves preserving glomerular endothelial cell integrity, reducing albuminuria, and mitigating inflammation and fibrosis.
- Ticagrelor holds promise as a therapeutic agent for managing diabetic kidney disease.
Abstract:
Diabetic nephropathy (DN) is a major complication of diabetes and is associated with high risk for cardiovascular mortality, which is partially related to elevated platelet activity. Platelets are also active players in inflammation and fibrosis. In this study, we examine the effect of ticagrelor-induced platelet inhibition on the development of DN. DN was induced by unilateral nephrectomy followed by streptozotocin injections for 5 days. Mice received ticagrelor (300 mg/kg) or vehicle every other day, for 16 weeks. Experimental groups: non-diabetic control, diabetic control, non-diabetic ticagrelor, and diabetic ticagrelor. Ticagrelor treatment in diabetic mice lowered urinary albumin excretion, it prevented diabetes-induced mesangial matrix expansion, podocyte effacement, and glomerular endothelial cell injury, which includes loss of endothelial fenestrations, ICAM-1 expression, and PECAM expression. In addition, ticagrelor treatment prevented collagen IV deposition and macrophage infiltration in the tubulointerstitium and these diabetic mice showed lower systemic and tubular inflammation and tubular apoptosis. This tubular protection is likely to be a result of protection to the glomerular endothelium by ticagrelor, which reduces albuminuria and albumin toxicity to the tubules and reduced tubular and interstitial inflammation and fibrosis. In conclusion, ticagrelor-induced platelet inhibition protects against renal injury in diabetic mice, likely by protecting the glomerular endothelial cells.
